Stock NANOFH NANOFORM FINLAND OYJ
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Nanoform Finland Oyj

Equities

NANOFH

FI4000330972

Market Closed - Nasdaq Helsinki
Other stock markets
 11:29:33 2024-06-04 am EDT 		5-day change 1st Jan Change
2 EUR +0.10% Intraday chart for Nanoform Finland Oyj -8.68% +26.18%
May. 30 Nanoform Finland Oyj Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 30 Transcript : Nanoform Finland Oyj, Q1 2024 Earnings Call, May 30, 2024

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • Based on current prices, the company has particularly high valuation levels.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
NANOFORM FINLAND OYJ Stock Nanoform Finland Oyj
+26.18% 186M -
MODERNA, INC. Stock Moderna, Inc.
+46.19% 56.65B
B-
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-6.14% 39.44B
B
LONZA GROUP AG Stock Lonza Group AG
+39.19% 39.03B
A
CELLTRION, INC. Stock Celltrion, Inc.
-6.65% 26.86B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.33% 26.75B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.78% 19.03B
B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-0.35% 12.28B
B+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+24.18% 12.26B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.38% 12.04B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. NANOFH Stock
  4. Ratings Nanoform Finland Oyj